XTL Biopharmaceuticals Opens U.S. Subsidiary
According to Martin Becker, president and CEO of XTL, the company will attempt, through the new subsidiary, to establish a firm foothold in the U.S., thus facilitating direct access to the world's largest market for pharmaceutical- and biotechnology-based products.
"Our operations in the U.S. will support XTL's business development activities and will lay the foundation for efficient introduction of XTL's product candidates into the American regulatory environment," Becker added.
Prior to joining XTL, Kazo served as vice president of Corporate Development at Focal Inc. (Lexington, MA), a public medical device firm. He was also a founding member of Enzon Inc., a drug delivery company, where he pioneered the development of two of the company's marketed drug products. Kazo has over 15 years of experience in business development, strategic planning, and general management for the biopharmaceutical industry, and he has managed a consulting practice focusing on emerging technologies.
XTL is a biopharmaceutical company that develops fully human monoclonal antibody-based therapeutics with a primary focus on infectious diseases.
For more information: Martin Becker, President and CEO, XTL Biopharmaceuticals Ltd., P.O. Box 370, Rehovot 76100, Israel. Tel: +972 8-940-5134. Fax: +972 8-940-5017. Email: Becker@xtlbio.com.